Trial Profile
A Study to Determine the Bioequivalence of SCH 530348 2.5 mg Tablets Containing a High and Low Percentage of Drug as the Free Base Within the Range Used in the Pivotal Phase 3 Efficacy and Safety Trials. (Protocol No. P06558)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Vorapaxar (Primary) ; Pantoprazole
- Indications Acute coronary syndromes
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 25 May 2011 New trial record